无动物源,科研级 提供 ≥95%(SDS-PAGE&SEC-HPLC) 纯度，适用于对基线干扰要求严格的色谱和分析工作流程。
-80℃储存,避免反复冻融。特低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
Lesabelimab (anti-PD-L1) 是一种免疫球蛋白 G1-kappa 抗 CD274 单克隆抗体。CD274 是一种免疫检查点配体，通过与 PDCD1 受体相互作用抑制抗肿瘤免疫。
Lesabelimab (anti-PD-L1) is an immunoglobulin G1-kappa anti-CD274 monoclonal antibody. CD274 is an immune checkpoint ligand, represses antitumour immunity through the interaction with PDCD1 receptor.
Purity
≥95% (SDS-PAGE&SEC)
Endotoxin Level
< 1.0EU/mg
Lesabelimab (anti-PD-L1) (Ab182969) - Flow Cytometry
Flow Cytometry analysis of 500 ng/mL Ionomycin (I139530) and 10 ng/mL PMA (P408905) co-stimulated Jurkat cells (24h) labelling PD-L1 (red) with Lesabelimab (anti-PD-L1) (Ab182969). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Lesabelimab (anti-PD-L1) (Ab182969) - ELISA
Immobilized Recombinant Human PD-L1 protein (rp169666) at 1.0 μg/mL can bind Lesabelimab (anti-PD-L1) (Ab182969) with the EC₅₀ of 172.4 ng/mL.
Lesabelimab (anti-PD-L1) (Ab182969) - SEC
The purity of Lesabelimab (anti-PD-L1) (Ab182969) is more than 95% verified by HPLC.
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
 ZJ24F1114103 |
分析证书 | Ab182969 |
| ZJ24F1114104 |
分析证书 | Ab182969 |
| ZJ24F1114105 |
分析证书 | Ab182969 |
| ZJ24F0606993 |
分析证书 | Ab182969 |
| ZJ24F0606994 |
分析证书 | Ab182969 |
| ZJ24F0606995 |
分析证书 | Ab182969 |
危险品化学品经营许可证（带存储）